The International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) has now endorsed Endoscopic Sleeve Gastroplasty (ESG) as an effective, minimally invasive option for weight loss! This endorsement highlights the growing recognition of ESG as a safe and reliable choice for individuals seeking non-surgical weight loss solutions.
The IFSO Bariatric Endoscopy Committee, after conducting a comprehensive systematic review and meta-analysis, endorses endoscopic sleeve gastroplasty (ESG) as an effective and valuable treatment for obesity. ESG is particularly beneficial for patients with class I and II obesity, as well as for those with class III obesity who are not suitable candidates for metabolic bariatric surgery. ESG provides significant weight loss outcomes and demonstrates a favorable safety profile with a low rate of serious adverse events. Despite the limitations of the included observational studies, the randomized controlled trial included in the analysis reinforces the efficacy and safety of ESG and provides an evidence-based foundation for the position statement. Thus, the IFSO position statement supports and provides an evidence base for the role of ESG within the broader spectrum of obesity management.
You can reach out the related article with the link below.
Comments